Irreversible targeting of mammalian thioredoxin reductase 1 (TrxR1) for anticancer therapy

不可逆靶向哺乳动物硫氧还蛋白还原酶 1 (TrxR1) 进行抗癌治疗

• 批准号: 9205742
• 负责人: Ajit Jadhav
• 金额: $ 11.4万
• 依托单位: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9205742
• 关键词: Irreversible; targeting; mammalian; thioredoxin; reductase

Project highlights: extended characterization of the current lead is being pursued in in vivo xenograft models. During this period, the NCGC has fostered and maintained over 180 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to over 100 high-throughput screens and nearly 60 medicinal chemistry campaigns, providing our collaborators and the general research community a wealth of publications and promising small molecule leads. In addition, the NCGC has undertaken a number of informatic challenges to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.

项目亮点：正在体内异种移植模型中对当前电极导线进行扩展表征。 在此期间，NCGC促进并保持了与NIH和校外研究人员的180多项积极合作，促进了整个人类疾病谱的药物发现工作。 这些努力已经导致了100多个高通量筛选和近60个药物化学活动，为我们的合作者和一般研究社区提供了丰富的出版物和有前途的小分子线索。 此外，NCGC还承担了一系列信息挑战，以更好地利用现有的药物和疾病靶点信息，并为公众提供易于获取的资源，进一步促进人类疾病新疗法的开发。